ALVR vs. CRIS, BLUE, VIGL, PLX, ATRA, PASG, CVM, GRTS, LIFE, and SGMO
Should you be buying AlloVir stock or one of its competitors? The main competitors of AlloVir include Curis (CRIS), bluebird bio (BLUE), Vigil Neuroscience (VIGL), Protalix BioTherapeutics (PLX), Atara Biotherapeutics (ATRA), Passage Bio (PASG), CEL-SCI (CVM), Gritstone bio (GRTS), aTyr Pharma (LIFE), and Sangamo Therapeutics (SGMO). These companies are all part of the "biological products, except diagnostic" industry.
Curis (NASDAQ:CRIS) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.
Curis presently has a consensus price target of $37.33, suggesting a potential upside of 130.45%. AlloVir has a consensus price target of $18.50, suggesting a potential upside of 2,223.25%. Given Curis' higher possible upside, analysts plainly believe AlloVir is more favorable than Curis.
Curis has higher revenue and earnings than AlloVir. Curis is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
AlloVir has a net margin of 0.00% compared to AlloVir's net margin of -473.04%. Curis' return on equity of -99.73% beat AlloVir's return on equity.
30.0% of Curis shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 5.7% of Curis shares are held by insiders. Comparatively, 33.9% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Curis had 1 more articles in the media than AlloVir. MarketBeat recorded 6 mentions for Curis and 5 mentions for AlloVir. AlloVir's average media sentiment score of 0.00 equaled Curis'average media sentiment score.
Curis received 657 more outperform votes than AlloVir when rated by MarketBeat users. Likewise, 67.52% of users gave Curis an outperform vote while only 57.45% of users gave AlloVir an outperform vote.
Curis has a beta of 3.59, suggesting that its share price is 259% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.
Summary
Curis beats AlloVir on 9 of the 16 factors compared between the two stocks.
Get AlloVir News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
